GW-1000. GW Pharmaceuticals.
GW Pharmaceuticals is developing GW-1000 (Sativex), a narrow ratio delta9-tetrahydrocannabinol:cannabidiol product for the potential treatment of multiple sclerosis, spinal cord injury, neurogenic pain and peripheral neuropathy. In March 2003, the company filed for approval for the treatment of MS with the UK Medicines Control Agency, and in May 2004, filed for new drug submission with Health Canada.
University of Otago, Department of Pharmacology and Toxicology, School of Medical Sciences, Dunedin, New Zealand. paul.smith@stonebow.otago.ac.nz
Paul F
PF
Smith
D000284:Administration, Oral; D000700:Analgesics / Q000008:administration & dosage / Q000378:metabolism / Q000493:pharmacokinetics; D000818:Animals; D001682:Biological Availability; D002170:Canada; D002185:Cannabidiol; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D013759:Dronabinol; D017277:Drug Approval / Q000379:methods; D004338:Drug Combinations; D004353:Drug Evaluation, Preclinical; D004345:Drug Industry; D006801:Humans; D006930:Hyperalgesia / Q000188:drug therapy; D017387:Investigational New Drug Application / Q000331:legislation & jurisprudence; D051379:Mice; D015394:Molecular Structure; D009103:Multiple Sclerosis / Q000188:drug therapy; D010330:Patents as Topic; D010523:Peripheral Nervous System Diseases / Q000188:drug therapy; D008517:Phytotherapy; D010936:Plant Extracts / Q000138:chemical synthesis / Q000494:pharmacology / Q000627:therapeutic use*; D028321:Plant Preparations / Q000737:chemistry / Q000302:isolation & purification; D016032:Randomized Controlled Trials as Topic; D013119:Spinal Cord Injuries / Q000188:drug therapy; D013329:Structure-Activity Relationship
D000700:Analgesics; D004338:Drug Combinations; D010936:Plant Extracts; D028321:Plant Preparations; D002185:Cannabidiol; D013759:Dronabinol; C587251:nabiximols